Market consensus does not universally classify Oscar Health as a strong buy, as Wall Street analyst opinions are divided between growth-oriented enthusiasm and cautious risk management. Bullish researchers emphasize its digital disruption capabilities and rapid revenue expansion across individual exchanges, whereas neutral or bearish analysts point to lingering regulatory risks, medical cost inflation, and earnings volatility. Investors must weigh these conflicting viewpoints against their own long-term portfolio objectives before committing capital.